カテゴリ： GlobalData, イギリス, 企業調査

Institute of Cancer Research-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Institute of Cancer Research - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8014365
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月22日
◆ページ数：63
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：イギリス
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Institute of Cancer Research (ICR), a subsidiary of University of London is a research institute that offers cancer research and education programs. The institute conducts research and develops new therapies for the treatment of cancer including breast and lung cancer. It offers various postgraduate and higher education programs in several streams. ICR conducts research services in areas of breast cancer, clinical studies, molecular pathology, genetics and epidemiology, radiotherapy and imaging, among others. The institute operates through collaborations with cancer research centers, and healthcare organizations. ICR is headquartered in London, the UK.

Institute of Cancer Research – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Institute of Cancer Research, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Institute of Cancer Research, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Institute of Cancer Research, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Institute of Cancer Research, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Institute of Cancer Research, Medical Devices Deals, 2011 to YTD 2017 10
Institute of Cancer Research, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Institute of Cancer Research, Pharmaceuticals & Healthcare, Deal Details 12
Private Equity 12
DRI Capital Acquires Partial Royalty Rights of Zytiga from Institute of Cancer Research 12
Partnerships 13
Merck Serono Enters into Co-Development Agreement with Institute of Cancer Research and Wellcome Trust 13
Nuevolution Enters Into Agreement With Cancer Research Technology And Institute Of Cancer Research For Drug Discovery 14
Cancer Research Technology And Institute of Cancer Research Enter Into Agreement With Merck Serono For Drug Discovery 16
Janssen Biotech Enters Into Agreement With CRT And ICR To Discover Multiple Myeloma Drug 17
Astex Pharma, Cancer Research Technology And Institute of Cancer Research Enter Into Epigenetic Drug Discovery Agreement 18
Cancer Research Technology, Institute of Cancer Research And ZoBio Enter Into Agreement To Develop Cancer Drugs 20
Licensing Agreements 21
Basilea Pharma Enters into Licensing Agreement for Novel PanRAF Kinase Inhibitors 21
Cancer Research Technology, Cardiff University, And Institute of Cancer Research Extend Licensing Agreement With Merck Serono 22
Institute of Cancer Research Enters Into Licensing Agreement With Dotmatics For Informatics Platform 24
Institute of Cancer Research – Key Competitors 25
Institute of Cancer Research – Key Employees 26
Institute of Cancer Research – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Government and Public Interest 28
Nov 16, 2017: ICR responds to NICE approval of new breakthrough drugs on the NHS for women with advanced breast cancer 28
Nov 07, 2017: NCRI 2017: Big data analysis predicts risk of radiotherapy effects 29
Sep 22, 2017: New treatment approach for rare type of triple negative breast cancers identified 30
Sep 10, 2017: Merck ‘Grant for Oncology Innovation’ awards recognize recipients for pushing boundaries in oncology research 32
Sep 05, 2017: New approach could better predict breast cancer risk due to family history 33
Aug 29, 2017: Bowel cancer study reveals impact of mutations on protein networks 35
Aug 02, 2017: Targeted radiotherapy limits side effects of breast cancer treatment 37
Jul 10, 2017: Scientists call for better use of chemical tools to improve cancer drug discovery 39
Jul 10, 2017: ICR awarded £30 million towards new Centre for Cancer Drug Discovery 40
May 30, 2017: Pioneering genetic research into myeloma is spearheading our search for new treatments 41
May 29, 2017: New genetic cause of kidney cancer in children discovered 42
May 16, 2017: Scientists build molecule to disrupt cancer protein 43
Mar 27, 2017: Largest ever brain cancer study reveals new secrets to inherited risk 44
Mar 27, 2017: ICR scientists awarded £1.5m precision medicine funding for targeted, less toxic childhood cancer treatments 46
Jan 12, 2017: Scientists discover powerful new inhibitor of cancer stress signal 47
Nov 24, 2016: New research uncovers mechanism for genetic risk of myeloma 49
Oct 26, 2016: Promising target for triple-negative breast cancers 50
Aug 22, 2016: Effect of combined HRT on breast cancer risk likely to have been underestimated, new study finds 51
Aug 09, 2016: Radiotherapy supercharges cancer-targeting viruses to treat deadly skin cancer 53
Jun 14, 2016: Targeted radiotherapy for head and neck cancer could reduce the risk of dry mouth 54
May 01, 2016: New cancer drugs could treat lethal resistant prostate cancers 55
Mar 10, 2016: Gene may worsen cancer outcome by speeding metabolism of drugs 57
Feb 02, 2016: Plans unveiled for UK’s new global hub for cancer research and treatment 59
Product News 62
Jun 06, 2017: New chemotherapy approach offers breast cancer patients a better quality of life 62
Appendix 63
Methodology 63
About GlobalData 63
Contact Us 63
Disclaimer 63

List of Tables
Institute of Cancer Research, Pharmaceuticals & Healthcare, Key Facts 2
Institute of Cancer Research, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Institute of Cancer Research, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Institute of Cancer Research, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Institute of Cancer Research, Deals By Therapy Area, 2011 to YTD 2017 9
Institute of Cancer Research, Medical Devices Deals, 2011 to YTD 2017 10
Institute of Cancer Research, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
DRI Capital Acquires Partial Royalty Rights of Zytiga from Institute of Cancer Research 12
Merck Serono Enters into Co-Development Agreement with Institute of Cancer Research and Wellcome Trust 13
Nuevolution Enters Into Agreement With Cancer Research Technology And Institute Of Cancer Research For Drug Discovery 14
Cancer Research Technology And Institute of Cancer Research Enter Into Agreement With Merck Serono For Drug Discovery 16
Janssen Biotech Enters Into Agreement With CRT And ICR To Discover Multiple Myeloma Drug 17
Astex Pharma, Cancer Research Technology And Institute of Cancer Research Enter Into Epigenetic Drug Discovery Agreement 18
Cancer Research Technology, Institute of Cancer Research And ZoBio Enter Into Agreement To Develop Cancer Drugs 20
Basilea Pharma Enters into Licensing Agreement for Novel PanRAF Kinase Inhibitors 21
Cancer Research Technology, Cardiff University, And Institute of Cancer Research Extend Licensing Agreement With Merck Serono 22
Institute of Cancer Research Enters Into Licensing Agreement With Dotmatics For Informatics Platform 24
Institute of Cancer Research, Key Competitors 25
Institute of Cancer Research, Key Employees 26
Institute of Cancer Research, Other Locations 27

★海外企業調査レポート[Institute of Cancer Research-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Medytox Inc (086900)：企業の財務・戦略的SWOT分析
    Summary Medytox Inc (Medytox) develops, manufactures and markets biopharmaceutical products. Its products include botulinum toxin type A product, hyaluronic acid filler, medical devices, prescription cream, toxin detection kits and antitoxin therapeutics for treating skin disorders. The company is a …
  • Sekisui Chemical Co Ltd (4204)：企業の財務・戦略的SWOT分析
    Sekisui Chemical Co Ltd (4204) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Hydro One Networks Inc：電力：M&Aディール及び事業提携情報
    Summary Hydro One Networks Inc (Hydro One), a subsidiary of Hydro One Ltd, is an electric utility service provider. The company offers residential services, business services, rates and billing, saving money and energy, power outages and safety services. It provides move in move out, submit a meter …
  • Royal FrieslandCampina N.V.：企業の戦略・SWOT・財務情報
    Royal FrieslandCampina N.V. - Strategy, SWOT and Corporate Finance Report Summary Royal FrieslandCampina N.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Cantargia AB (CANTA)：製薬・医療：M&Aディール及び事業提携情報
    Summary Cantargia AB (Cantargia), a subsidiary of Lund University Bioscience AB is a biotechnology company that develops antibody based cancer treatments. The company’s product candidate CAN04 is used for the treatment of several cancers including non-small cell lung cancer and pancreatic cancer. It …
  • Galmed Pharmaceuticals Ltd (GLMD)：製薬・医療：M&Aディール及び事業提携情報
    Summary Galmed Pharmaceuticals Ltd (Galmed Pharmaceuticals), a subsidiary of Galmed International Ltd, is a clinical-stage biopharmaceutical company. The company focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in ARREST …
  • Sun Pharma Advanced Research Company Ltd (SPARC)-製薬・医療分野：企業M&A・提携分析
    Summary Sun Pharma Advanced Research Company Ltd (SPARC), a subsidiary of Sun Pharmaceutical Industries Ltd is a pharma research and drug discovery company that conducts research and and produces drugs. The company develops active pharmaceutical ingredients, formulations and drug delivery technologi …
  • University of Texas Southwestern Medical Center-製薬・医療分野：企業M&A・提携分析
    Summary University of Texas Southwestern Medical Center (UTSMC), a subsidiary of University of Texas System is an educational center that offers medical research and education programs. The center offers degree programs, which include master's degree in business administration, public health, medica …
  • Technip SA (TEC)-石油・ガス分野：企業M&A・提携分析
    Summary Technip SA (Technip) is a provider of project management, engineering and construction services to energy sector. It offers a comprehensive portfolio of technologies and services for the subsea oil and gas developments to the largest and most complex offshore and onshore infrastructures. The …
  • Global Business Power Corp：電力：M&Aディール及び事業提携情報
    Summary Global Business Power Corp (GBPC), formerly Mirant Global Corp, a subsidiary of ORIX Corp, is an energy utility that generates and distributes electricity. The utility produces reliable and cost-efficient power supply through its subsidiaries that operate power generation facilities. Its ser …
  • Hilton Worldwide Holdings Inc：企業のM&A・事業提携・投資動向
    Hilton Worldwide Holdings Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Hilton Worldwide Holdings Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Hindustan Oil Exploration Co Ltd (HINDOILEXP)：企業の財務・戦略的SWOT分析
    Summary Hindustan Oil Exploration Co Ltd (HOEC) is an oil and gas exploration and development company. The company’s business activities include exploration and development of hydrocarbons crude oil and natural gas. It offers geological and geophysical services related to the exploration of oil and …
  • All in West! Capital Corporation：企業の戦略・SWOT・財務情報
    All in West! Capital Corporation - Strategy, SWOT and Corporate Finance Report Summary All in West! Capital Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Optimum General Inc.：企業の戦略・SWOT・財務情報
    Optimum General Inc. - Strategy, SWOT and Corporate Finance Report Summary Optimum General Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Dr. Ci:Labo Co., Ltd.：企業の戦略・SWOT・財務情報
    Dr. Ci:Labo Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Dr. Ci:Labo Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Exiqon AS：製薬・医療：M&Aディール及び事業提携情報
    Summary Exiqon AS (Exiqon), a subsidiary of Qiagen NV, is a medical device company that develops, manufactures and markets molecular diagnostic test products. The company provides product categories such as microRNA research, incRNA research, mRNA research, DNA research, custom oligos and other reag …
  • Depuy Synthes Companies
    Depuy Synthes Companies - Strategy, SWOT and Corporate Finance Report Summary Depuy Synthes Companies - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • OsteoVantage Inc：製品パイプライン分析
    Summary OsteoVantage Inc (OsteoVantage) is a medical device company that develops osteogenic spinal instrumentation technology used in spinal fusion procedures. The company’s INDOS system is an osteogenic spinal instrumentation for use in lumbar spinal fusion procedures. It also offers osteomodulati …
  • OGE Energy Corp (OGE)：企業の財務・戦略的SWOT分析
    OGE Energy Corp (OGE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • IJM Land Berhad：企業の戦略・SWOT・財務情報
    IJM Land Berhad - Strategy, SWOT and Corporate Finance Report Summary IJM Land Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆